# Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

Study · id `cardio:ct-nct03895502` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03895502](<https://clinicaltrials.gov/study/NCT03895502>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03895502

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 605 participants.

## Technical summary

Registry record NCT03895502. Randomized; no masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2023-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 605 participants (enrolled count; ClinicalTrials.gov record NCT03895502, source copy `cardio:ctgov-nct03895502-2023-10-04`, retrieved 2026-10-31)
- Started: 2019-05-27 (actual) (ClinicalTrials.gov record NCT03895502, source copy `cardio:ctgov-nct03895502-2023-10-04`, retrieved 2026-10-31)
- Primary completion: 2023-06-30 (actual) (ClinicalTrials.gov record NCT03895502, source copy `cardio:ctgov-nct03895502-2023-10-04`, retrieved 2026-10-31)
- Completion: 2023-08-31 (actual) (ClinicalTrials.gov record NCT03895502, source copy `cardio:ctgov-nct03895502-2023-10-04`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT03895502, source copy `cardio:ctgov-nct03895502-2023-10-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03895502-2023-10-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
- Acronym: ONCO DVT
- Condition: Venous Thrombosis
- Condition: Neoplasms
- Condition: Anticoagulant
- Intervention (Drug): 12-month Edoxaban
- Intervention (Drug): 3-month Edoxaban
- Lead sponsor: Takeshi Morimoto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry lists this organization as the lead sponsor: Takeshi Morimoto (`cardio:org-takeshi-morimoto`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial (`cardio:pubmed-37638968`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study (`cardio:pubmed-38650055`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: dac19df87ca71e7006d26fc5dad209b8911a89acb0ce65d522fac9f2a2d34245
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
